The Correlation Between C-Reactive Protein (CRP) and Interleukin-33 (IL-33) Levels in Ulcerative Colitis Patients with and without Entamoebiasis in Al-Najaf Governorate
DOI:
https://doi.org/10.63939/cskh0s51Keywords:
Ulcerative Colitis, Entamoeba histolytica, C-Reactive Protein, Interleukin-33, Al-Najaf Governorate, ROC AnalysisAbstract
Background: The disease of Ulcerative Colitis (UC) is chronic mucosal ulcer formation. In endemic areas such as the Al-Najaf Governorate, double infections with protozoa like Entamoeba histolytica are common and complicate the clinical presentation. Objective: To evaluate and compare the diagnosis relevance of systemic C-reactive protein (CRP) and mucosal IL-33 in UC patients with and without comorbid entamoebiasis. Methods: A comparative cross-section study was conducted on 90 individuals, aged 10-40 years, were taken from Gastroenterology Center, Al-Zahra Teaching Hospital and Al-Sadr Teaching Hospital at the city of Al-Najaf in the period from December 2025 to May 2026. The subjects were divided into three equal groups of 30 each: group 1 (Entamoebiasis only), group 2 (UC only), group 3 (UC and Entamoebiasis co-infection). Serum CRP and IL-33 concentrations were measured by automated immunoturbidimetry and Enzyme-Linked Immunosorbent Assay (ELISA), respectively. Diagnostic performance was assessed by Receiver Operating Characteristic (ROC) curve analysis. Results: The serum CRP and IL-33 were markedly increased in co-infection group (48.62±8.34 mg/L and 214.50±35.20 pg/mL, respectively) in comparison with Group 1 and Group 2 (P<0.001). Highly significant strong positive association was observed between CRP and IL-33 in co-infected group (r=0.742, P<0.001). ROC curve analysis demonstrated that serum IL-33 had the best diagnostic value to predict parasitic co-infection in UC subjects (AUC = 0.912, Sensitivity = 90.0%, Specificity = 86.7%) at cut off value of >172.45 pg/mL. Conclusion: Entamoebiasis co-existing with ulcerative colitis and negatively influencing systemic and mucosal inflammation in those patients. The combined monitoring of CRP and IL-33 levels is a dependable non-invasive tool to detect parasitic complications in the context of acute UC relapses, thus avoiding detrimental clinical errors.
Downloads
References
1. R. Ungaro et al., "Ulcerative colitis," The Lancet, vol. 389, no. 10080, pp. 1756–1770, 2017.
2. I. Ordás et al., "Ulcerative colitis," The Lancet, vol. 380, no. 9853, pp. 1606–1619, 2012.
3. H. N. Iskandar and M. A. Ciorba, "Biomarkers in inflammatory bowel disease: Current practices and recent advances," Translational Research, vol. 175, pp. 41–55, 2016.
4. L. A. Al-Shibani et al., "Epidemiological assessment of intestinal amoebiasis in Al-Najaf Province," Iraqi J. Med. Sci., vol. 19, no. 2, pp. 154–162, 2021.
5. S. Ghosh et al., "The overlapping clinical and histological spectrum of amoebic colitis and inflammatory bowel disease," J. Clin. Gastroenterol., vol. 53, no. 6, pp. 411–419, 2019.
6. [6] E. J. Balthazar et al., "Fulminant amoebic colitis and toxic megacolon," J. Comput. Assist. Tomogr., vol. 38, no. 4, pp. 512–518, 2014.
7. S. Vermeire et al., "C-reactive protein as a biomarker in inflammatory bowel disease," Inflamm. Bowel Dis., vol. 10, no. 5, pp. 661–665, 2004.
8. S. Karoui et al., "Diagnostic accuracy of C-reactive protein and erythrocyte sedimentation rate in predicting severe flares of ulcerative colitis," Tunisie Médicale, vol. 89, no. 6, pp. 522–526, 2011.
9. C. Cayrol and J. P. Girard, "IL-33: an alarmin cytokine with crucial roles in innate immunity," Curr. Opin. Immunol., vol. 31, pp. 31–37, 2014.
10. G. Haraldsen et al., "Interleukin-33: the alarmin cytokine that sounds the immune alarm," Trends Immunol., vol. 30, no. 5, pp. 227–233, 2009.
11. L. Pastorelli et al., "Epithelial-derived IL-33 and its receptor ST2 in ulcerative colitis," Proc. Natl. Acad. Sci. USA, vol. 107, no. 26, pp. 11918–11923, 2010.
12. L. R. Lopetuso et al., "The therapeutic potential of Interleukin-33 in inflammatory bowel disease," World J. Gastroenterol., vol. 18, no. 38, pp. 5340–5348, 2012.
13. M. Henriksen et al., "C-reactive protein in the initial assessment of disease activity in ulcerative colitis," Am. J. Gastroenterol., vol. 103, no. 12, pp. 3074–3080, 2008.
14. S. Begum et al., "Entamoeba histolytica cysteine proteases cleave the mucin polymer MUC2," Gastroenterology, vol. 148, no. 4, pp. 784–794, 2015.
15. D. T. Shirley et al., "A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis," Open Forum Infect. Dis., vol. 5, no. 7, 2018.
16. H. Moura et al., "Parasite-induced pro-inflammatory cytokine expression in human colonic loops," Infect. Immun., vol. 77, no. 11, pp. 4812–4820, 2009.
17. L. G. Soong et al., "Intestinal tissue responses and chemokine production during early stages of intestinal amebiasis," J. Infect. Dis., vol. 206, no. 8, pp. 1224–1233, 2012.
18. J. B. Seidelin et al., "IL-33 is upregulated in inflamed mucosa of ulcerative colitis and acts as an intracellular alarmin," Inflammation Res., vol. 59, no. 7, pp. 515–521, 2010.
19. C. J. Beltrán et al., "Characterization of the novel alarmin IL-33 and its receptor ST2 in the intestinal mucosa," Inflamm. Bowel Dis., vol. 16, no. 10, pp. 1625–1633, 2010.
20. K. S. Ralston et al., "Trogocytosis by Entamoeba histolytica contributes to cell death and tissue destruction," Nature, vol. 508, no. 7497, pp. 526–530, 2014.
21. F. N. Sedeh et al., "Disruption of colonic tight junctions by pathogenic protozoa," Parasitol. Int., vol. 63, no. 2, pp. 311–317, 2014.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Progressive Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
